NasdaqGM - Delayed Quote • USD
Bionomics Limited (BNOX)
At close: May 28 at 4:00 PM EDT
After hours: May 28 at 7:38 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2022) | Next Qtr. (Jun 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2022) | Next Qtr. (Jun 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 3 | 2 |
| Avg. Estimate | -- | -- | 182k | 15k |
| Low Estimate | 250k | 250k | -620k | 940k |
| High Estimate | 250k | 250k | 620k | 5.54M |
| Year Ago Sales | -- | -- | -- | 182k |
| Sales Growth (year/est) | -- | -- | -- | -91.80% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2022) | Next Qtr. (Jun 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.46 | -0.54 | -1.16 | -1.86 |
| 30 Days Ago | -0.46 | -0.54 | -1.16 | -1.86 |
| 60 Days Ago | -0.46 | -0.54 | -1.16 | -1.86 |
| 90 Days Ago | -0.46 | -0.54 | -1.16 | -1.86 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2022) | Next Qtr. (Jun 2022) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BNOX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 7.90% |
| Next Qtr. | -- | -- | -- | 10.20% |
| Current Year | -- | -- | -- | 4.80% |
| Next Year | -- | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/7/2023 |
| Maintains | Maxim Group: Buy to Buy | 9/28/2023 |
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 9/28/2023 |
| Initiated | Maxim Group: Buy | 6/16/2023 |
| Upgrade | Evercore ISI Group: In-Line to Outperform | 3/10/2023 |
Related Tickers
PTIX Protagenic Therapeutics, Inc.
1.5450
-4.04%
NKGN NKGen Biotech, Inc.
1.5000
+5.63%
ATNF 180 Life Sciences Corp.
1.6200
0.00%
NBY NovaBay Pharmaceuticals, Inc.
0.1410
+6.98%
INM InMed Pharmaceuticals Inc.
0.2875
-5.21%
ONCO Onconetix, Inc.
0.1639
-9.90%
TOVX Theriva Biologics, Inc.
0.2710
-11.44%
CING Cingulate Inc.
0.7077
-10.77%
ALLR Allarity Therapeutics, Inc.
0.5752
-0.10%
TCBP TC Biopharm (Holdings) Plc
1.1400
+0.88%